|Bid||272.24 x 200|
|Ask||272.46 x 200|
|Day's Range||269.09 - 273.53|
|52 Week Range||232.00 - 333.65|
|PE Ratio (TTM)||17.10|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Since being launched in 2014 with financing from Fidelity and other prominent investors, Cambridge-based Scholar Rock has been developing a drug that is designed to block a protein that limits muscle growth. On Wednesday, the privately-held, 40-employee company revealed for the first time which disease it plans to target: spinal muscular atrophy, or SMA, a leading genetic cause of death in infants. There was no approved treatment for SMA until December 2016, when the FDA green-lighted Biogen's (BIIB) Spinraza.
When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here's why.
Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ...